Perception of COVID-19 Pandemic Among IBD Clinicians and IBD Surgeons in Black Sea Region: A Cross-Sectional Questionnaire Study.

Background: Since December 2019, the COVID-19 pandemic has created an increasing challenge in managing inflammatory bowel dis- ease patients both medically and surgically. Although several international and national medical/surgical associations published guide- lines in this area, there is still a huge difference between daily practices and these guidelines, especially depending on regional practices and governmental policies. Therefore, we aimed to investigate and define gastroenterologists' and surgeons' fear of COVID-19 and how they have managed inflammatory bowel disease patients during this pandemic in the Black Sea region.

[Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].

Unlabelled: Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clinical practice in patients with various forms of ulcerative colitis (UC) and Crohns disease (CD).

Certolizumab pegol in treatment of Crohn's disease with perianal lesions.

Aim: To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions.

Materials And Methods: The study included 20 patients with CD with perianal fistulae. Prior to the start of conservative therapy, 7 patients underwent fistulae drainage with setton placement.

[Efficiency of tacrolimus therapy for perianal Crohn's disease].

Aim: To determine the efficacy of 0.1% tacrolimus ointment in patients with perianal Crohn's disease (CD).

Subjects And Methods: This prospective randomized trial enrolled 20 patients with perianal CD as anal fissures and rectal fistulas.

[Long-term results of medical treatment in patients with a severe attack of ulcerative colitis].

Aim: To assess the long-term result of medical treatment in patients with a severe attack (SA) of ulcerative colitis (UC).

Subjects And Methods: The course of UC was analyzed in 56 patients who were accessible by telephone contact and consecutively recruited for a year after therapy for a SA of UC. All the patients were stated to have a SA of UC according to the Truelove-Witts' criteria; they received therapy with intravenous glucocorticosteroids (GCS) (prednisolone 2 mg/kg) along with anti-recurrence therapy with mesalasine (5-ASA) or azathioprine (AZA).